Share-based Payment Arrangement, Expense of Tyra Biosciences, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Tyra Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Tyra Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $7,577,000, a 0.05% increase year-over-year.
  • Tyra Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $27,081,000, a 34% increase year-over-year.
  • Tyra Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $22,801,000, a 69% increase from 2023.
  • Tyra Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $13,525,000, a 28% increase from 2022.
  • Tyra Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,588,000, a 267% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Tyra Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $27,081,000 $7,577,000 +$4,000 +0.05% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $27,077,000 $6,380,000 +$1,969,000 +45% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $25,108,000 $6,422,000 +$2,307,000 +56% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $22,801,000 $6,702,000 +$2,516,000 +60% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $20,285,000 $7,573,000 +$3,196,000 +73% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $17,089,000 $4,411,000 +$1,882,000 +74% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $15,207,000 $4,115,000 +$1,682,000 +69% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $13,525,000 $4,186,000 +$1,276,000 +44% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $12,249,000 $4,377,000 +$3,358,000 +330% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $8,891,000 $2,529,000 -$158,000 -5.9% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $9,049,000 $2,433,000 -$1,539,000 -39% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $10,588,000 $2,910,000 +$1,043,000 +56% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $9,545,000 $1,019,000 +$511,000 +101% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $9,034,000 $2,687,000 +$2,349,000 +695% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $6,685,000 $3,972,000 +$3,798,000 +2183% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $2,887,000 $1,867,000 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $508,000 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $338,000 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $174,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1

Tyra Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $22,801,000 +$9,276,000 +69% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $13,525,000 +$2,937,000 +28% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $10,588,000 +$7,701,000 +267% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $2,887,000 +$2,448,000 +558% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $439,000 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.